JP5926965B2 - Body fluid leakage prevention agent - Google Patents

Description

  The present invention relates to an agent for preventing leakage of body fluid that is loaded into a body cavity of a body in order to prevent body fluid from leaking from the body.

  The human body may leak bodily fluids such as gastric fluid, lung fluid, ascites, and excreta after death. For this reason, after confirming death, body cavities such as the mouth, nose, ears, anus, and cavity of the corpse are loaded with gauze or absorbent cotton to prevent leakage of bodily fluids. Similar measures are also taken for the opening of the body after an accident or surgery. However, many loading operations such as gauze and absorbent cotton into body cavities are often performed by employees or nurses. In addition to the complexity and unsanitary nature of the work, gauze, absorbent cotton, and the like have a low water absorption capability, and thus there is a problem that body fluid often leaks during or after the work. In addition, there was a possibility of post-mortem infection due to this spilled substance during work, and there was a strong need for a solution.

  For this reason, it is known to load a water-absorbing resin into the mouth, nose, ears, throat, etc. instead of gauze, absorbent cotton, or the like. For example, a method is known in which a jelly-like body fluid leakage preventing agent containing a water-absorbent resin is loaded into the mouth, nose, and ear using a loader (Patent Document 1).

  Also disclosed is a bodily fluid leakage preventing agent in which a water-absorbing resin is dispersed in a mucus base material in which a dispersion stabilizer such as carboxyvinyl polymer and a water-soluble thickener are dissolved in an alcohol such as polyethylene glycol (patent) Reference 2).

JP 2002-275001 A JP 2009-179581 A

  The body fluid leakage preventing agent of Patent Document 1 has a high fluidity and is loaded even in a narrow body cavity such as a nasal cavity or an ear canal because a water-absorbing resin is dispersed in a jelly mainly composed of alcohol. Cheap. However, there is still room for improvement in fluidity and water absorption performance.

  Moreover, even the bodily fluid leakage preventing agent of Patent Document 2 has a large loading resistance and lacks fluidity and water absorption performance.

  In particular, any body fluid leakage preventive agent may not be able to be loaded unless it is pushed firmly in the latter half of loading when it is loaded into a body cavity using a loader or the like. This phenomenon is presumed to be due to the fact that the mucous base material decreases in the latter half of the loading and a large amount of water-absorbing resin remains.

  An object of the present invention is to provide a bodily fluid leakage preventing agent having excellent fluidity and high water absorption performance. In particular, an object of the present invention is to provide a bodily fluid leakage preventing agent that can be loaded into a body cavity with a light force when loaded using an instrument such as a loader.

The present invention relates to a bodily fluid leakage preventing agent loaded in a body cavity of a corpse, and the bodily fluid leakage preventing agent includes at least one selected from the group consisting of alcohols, ethers and esters. A water-absorbing rate of physiological saline is 80 seconds or less, a crosslinked water-absorbing resin having a median particle size of 20 μm to 400 μm is dispersed, and the median particle size is 10 to 10 as a dispersion stabilizer. It contains 100 μm of non-crosslinked polyacrylic acid partial neutralized product.

  As the alcohols, for example, at least one of ethylene glycol, propylene glycol, diethylene glycol, polyethylene glycol, and glycerin can be used.

  Preference is given to further containing a carboxyvinyl polymer as a dispersion stabilizer.

As the water-absorbing resin, various materials such as a granular water-absorbing resin shown in FIG. 1, a spherical water-absorbing resin shown in FIG. 2, and a spherical agglomerated water-absorbing resin shown in FIG. 3 can be used . But are not limited constant, if example embodiment, preferably employed water-absorption rate of saline is less than 10 seconds the water-absorbent resin, and water-absorbing resin absorption rate is 80 seconds or less 15 seconds or more saline can do.

  As the water absorbent resin, one type of water absorbent resin can be used alone, or a plurality of different types of water absorbent resins can be used in combination.

  The median particle diameter of the water-absorbing resin having a water absorption rate of 10 seconds or less is preferably 20 μm or more and 300 μm or less, and the water absorption rate of the physiological saline is 15 seconds or more and 80 seconds or less. The median particle diameter of the resin is preferably 180 μm or more and 400 μm or less.

  The neutralization degree of the polyacrylic acid partial neutralized product is preferably 40% or more and 80% or less.

  The content of the water absorbent resin is preferably 10% by mass or more and 60% by mass or less.

  The content of the partially neutralized polyacrylic acid is preferably 0.05% by mass or more and 5% by mass or less.

  The viscosity of the body fluid leakage preventing agent is preferably 80,000 mPa · S or more and 200,000 mPa · S or less.

  The pH of the body fluid leakage preventing agent is preferably 6 or more and 9 or less.

According to the present invention, in the mucus substrate containing at least one selected from the group consisting of alcohols, ethers and esters, the water absorption rate of physiological saline is 80 seconds or less, and the median particle size is 20 μm. The body fluid leakage preventing agent in which the crosslinked water-absorbing resin having a particle size of 400 μm or less is dispersed contains a non-crosslinked polyacrylic acid partial neutralized product having a median particle diameter of 10 to 100 μm as a dispersion stabilizer. Therefore, phase separation between the water absorbent resin and the mucus substrate is suppressed. As a result, the fluidity of the body fluid leakage preventing agent is improved, and it is easy to load the body fluid into the body cavity.

  In particular, when a body fluid leakage preventing agent is loaded into a body cavity using an instrument such as a loader, the body cavity can be smoothly loaded from the beginning to the end with a light force.

It is a scanning electron micrograph which shows an example of a granular water absorbing resin. It is a scanning electron micrograph which shows an example of a true spherical water-absorbing resin. It is a scanning electron micrograph which shows an example of a true spherical aggregate water-absorbing resin. It is a figure explaining the use condition of the bodily fluid leakage prevention agent which concerns on embodiment of this invention. It is side surface sectional drawing of the syringe and piston which concern on embodiment. It is a perspective view of a supply pipe concerning an embodiment. It is a partial expanded sectional view explaining connection with a supply pipe concerning an embodiment. It is a figure which shows typically the evaluation test apparatus of a bodily fluid leakage prevention agent. It is a graph which shows the evaluation result of Examples 1-6 and Comparative Example 1. It is a graph which shows the evaluation result of Examples 8-15. It is a graph which shows the evaluation result of Examples 16-21 and the comparative example 2. FIG. It is a graph which shows the evaluation result of Examples 22-25.

  Hereinafter, embodiments for carrying out the present invention will be described with reference to the drawings. The following description of the preferred embodiments is merely exemplary in nature and is not intended to limit the invention, its application, or its use.

  The body fluid leakage preventing agent according to a preferred embodiment of the present invention has a water absorbent resin dispersed in a mucus base material containing at least one selected from the group consisting of alcohols, ethers and esters, and the water absorption A carboxyvinyl polymer and a partially neutralized polyacrylic acid are contained as a dispersion stabilizer for the conductive resin.

(Alcohol)
As the alcohols, various hydrophilic substances that are liquid at the use temperature of the body fluid leakage preventing agent (for example, 0 ° C. or more and 40 ° C. or less) can be used. For example, but not limited to, ethylene glycol, propylene glycol, diethylene glycol, polyethylene glycol, methyl alcohol, ethyl alcohol, n-propyl alcohol, isopropyl alcohol, n-butyl alcohol, isobutyl alcohol, t-butyl alcohol, glycerin, etc. Can be mentioned. Of these, glycols such as ethylene glycol, propylene glycol, diethylene glycol, and polyethylene glycol, and glycerin are preferable from the viewpoint of the stability of the dispersed state of the water-absorbent resin, and ethylene glycol, polyethylene glycol, and glycerin are particularly easy to handle. preferable.

(Ethers and esters)
As the ethers and esters, any hydrophilic compound that is liquid at the above use temperature can be used, but at least one selected from the group consisting of polyoxyethylene dimethyl ether and polyoxyethylene fatty acid diester is particularly suitable. Can be used. The polyoxyethylene fatty acid diester is represented by the general formula R1COO (CH2CH2O) nCOR2, and R1 and R2 are preferably alkyl groups having 17 or less carbon atoms. Here, R1 and R2 may be the same or different. Examples of the polyoxyethylene fatty acid diester include polyethylene glycol dilaurate and polyethylene glycol dioleate. Among these, polyoxyethylene dimethyl ether is preferable. The degree of polymerization of ethers and esters is not particularly limited as long as it is a degree of polymerization that becomes liquid at the above use temperature.

(Carboxyvinyl polymer)
Examples of the carboxyvinyl polymer include α, β-unsaturated compounds obtained by polymerizing a polymerizable material containing α, β-unsaturated carboxylic acids and a compound having two or more ethylenically unsaturated groups as a crosslinking agent. Examples include crosslinked products of saturated carboxylic acids.

  The α, β-unsaturated carboxylic acids used in the polymerizable material described above are not limited, and examples thereof include acrylic acid, methacrylic acid, crotonic acid, maleic acid, itaconic acid, and fumaric acid. .

  The compound having two or more ethylenically unsaturated groups is not particularly limited, and examples thereof include 2-ester or more acrylic acid esters of polyol, 2-aryl or more allyl ethers of polyol, diallyl phthalate, phosphorus Examples include triallyl acid, allyl methacrylate, tetraallyloxyethane, triallyl cyanurate, divinyl adipate, vinyl crotonic acid, 1,5-hexadiene, and divinylbenzene. Here, as a polyol for forming acrylic acid esters and allyl ethers, for example, ethylene glycol, propylene glycol, polyoxyethylene glycol, polyoxypropylene glycol, glycerin, polyglycerin, trimethylolpropane, pentaerythritol, Saccharose and sorbitol can be mentioned.

  The carboxyvinyl polymer can be produced by polymerizing a predetermined polymerizable material such as the above-described polymerizable material in an inert solvent in the presence of a radical polymerization initiator, and has water dispersibility.

(Water absorbent resin)
As the water-absorbing resin, various resins can be employed, and are not limited to, for example, a crosslinked product of an acrylate polymer and a crosslinked product of a hydrolysis product of a starch-acrylate graft copolymer. , Saponified products of vinyl alcohol-acrylate copolymer, maleic anhydride grafted polyvinyl alcohol, crosslinked isobutylene-maleic anhydride copolymer, vinyl acetate-acrylate copolymer, etc. Can be mentioned. Among these, a cross-linked product of an acrylate polymer that can absorb a large amount of liquid to form a water-insoluble gel, and can stably hold the absorbed liquid in the molecule even under some load. Is preferably used.

  Specific examples of the acrylate include lithium acrylate, sodium acrylate, potassium acrylate, ammonium acrylate, and the like. Among these acrylates, sodium acrylate and potassium acrylate are preferable, and sodium acrylate is more preferable.

  The particle shape of the water-absorbent resin may be granular, spherical, or spherical aggregate. Such a water-absorbent resin can be produced by a typical production method such as a reverse phase suspension polymerization method or an aqueous solution polymerization method. Moreover, what was manufactured with the various polymerization method can also be adjusted by grind | pulverizing, granulating, or classifying as needed.

Further, in order to quickly stop bodily fluid leakage, it is preferable that the water absorption rate of the water absorbent resin is large , that is, the water absorption rate of physiological saline is 80 seconds or less. For example, the water absorption rate of physiological saline is 10 seconds or less, the granular or true spherical water-absorbing resin having a median particle diameter of 20 μm or more and 300 μm or less, or the water absorption rate of physiological saline is 15 seconds or more and 80 seconds or less. In addition, a spherically aggregated water-absorbing resin having a median particle size of 180 μm or more and 400 μm or less can be suitably used.

  Here, although the granular or true spherical water-absorbing resin has a high water absorption rate, it is inferior in fluidity and easily aggregated compared to a true spherical aggregate, so that a limited amount of mucus base material is used. It is difficult to disperse in large quantities. On the other hand, the sphere-aggregated water-absorbent resin has a low water absorption rate, but has good fluidity and is difficult to aggregate, so that it can be easily dispersed in a relatively large amount with respect to the mucus substrate.

  The granular water-absorbing resin, the spherical spherical water-absorbing resin, and the true spherical aggregated water-absorbing resin may be used alone or in combination. For example, in a case where leakage of bodily fluid is quickly stopped, a bodily fluid leakage preventing agent in which only a granular or true spherical water-absorbing resin having a high water absorption rate is dispersed may be used. Alternatively, when two or more water-absorbing resins are used in combination, a body fluid leakage preventing agent having a large proportion of granular or spherical water-absorbing resin may be used. Further, in a case where a large amount of body fluid is expected to leak, a body fluid leakage preventing agent in which only the above-described highly spherical aggregated water absorbent resin is dispersed in a large amount may be used as the water absorbent resin. Alternatively, when two or more water-absorbing resins are used in combination, a bodily fluid leakage preventing agent having a large proportion of the true spherical aggregated water-absorbing resin may be used.

  The median particle diameter of the water absorbent resin is preferably 20 to 400 μm from the viewpoint of obtaining good fluidity.

  The content of the water absorbent resin is preferably 10 to 60% by mass. When the content of the water absorbent resin is less than 10% by mass, there is a possibility that the body fluid is absorbed and leakage cannot be prevented. On the other hand, when the content of the water-absorbing resin exceeds 60% by mass, there is a possibility that the fluidity is deteriorated and the body cavity cannot be smoothly loaded.

  The water absorption rate of the physiological saline is determined by the following method. That is, in a room adjusted to 25 ° C. ± 1 ° C., 50 ± 0.1 g of physiological saline is weighed into a 100 mL beaker, and a magnetic stirrer bar (no ring of 8 mmφ × 30 mm) is charged. The beaker is immersed in a constant temperature water bath and the liquid temperature is adjusted to 25 ± 0.2 ° C. Next, a beaker is placed on the magnetic stirrer, and a vortex is generated in the physiological saline at a rotation speed of 600 r / min. In that state, 2.0 ± 0.002 g of water-absorbing resin is quickly added to the beaker, and using a stopwatch, the time (seconds) from when the water-absorbing resin is added to when the liquid surface vortex converges Is taken as the water absorption rate of the water absorbent resin.

  The median particle diameter is a value measured by the following method. JIS standard sieve from above, sieve with an opening of 850 μm, sieve with an opening of 500 μm, sieve with an opening of 250 μm, sieve with an opening of 180 μm, sieve with an opening of 150 μm, sieve with an opening of 106 μm, sieve with an opening of 75 μm, and saucer 100 g of water-absorbing resin is put on the uppermost sieve combined in the order of, and classified by shaking for 20 minutes using a low-tap shaker. After classification, the mass of the water-absorbent resin remaining on each sieve is calculated as a percentage by mass with respect to the total amount, and the mass of the water-absorbent resin remaining on the sieve opening and the sieve is calculated by integrating in order from the larger particle size. The relationship between the percentage and the integrated value is plotted on a logarithmic probability paper. By connecting the plots on the probability paper with a straight line, the particle diameter corresponding to an integrated mass percentage of 50 mass% is defined as the median particle diameter.

(Polyacrylic acid partially neutralized product)
The partially neutralized polyacrylic acid (non-crosslinked type) is preferably one whose polymerization degree is controlled so that an extremely low molecular weight substance or an extremely high molecular weight substance is not formed when acrylic acid and its salt are polymerized. Used. The particle shape of the partially neutralized polyacrylic acid is not particularly limited, such as spherical or crushed, but is preferably spherical. Such a partially neutralized polyacrylic acid can be produced by various polymerization methods in addition to a typical production method such as a reverse phase suspension polymerization method and an aqueous solution polymerization method. Moreover, it can prepare by grind | pulverizing, granulating, or classifying as needed, and has water solubility.

  Specific examples of the acrylate include lithium acrylate, sodium acrylate, potassium acrylate, ammonium acrylate, and the like. Among these acrylates, sodium acrylate and potassium acrylate are preferable, and sodium acrylate is more preferable.

  The neutralization degree of the polyacrylic acid partial neutralized product is usually preferably 40 to 80%, more preferably 50 to 70%. If the degree of neutralization of the partially neutralized polyacrylic acid is less than 40%, the pH may decrease and the liquid absorption may decrease. On the other hand, when the neutralization degree of the polyacrylic acid partial neutralized product exceeds 80%, the gel may become soft and may not be intensively loaded at a necessary site.

  10-100 micrometers is preferable and, as for the median particle diameter of polyacrylic acid partial neutralized material, 20-80 micrometers is more preferable. When the median particle diameter of the partially neutralized polyacrylic acid is less than 10 μm or more than 100 μm, the fluidity may be deteriorated.

  The content of the partially neutralized polyacrylic acid is usually preferably 0.05 to 5% by mass, and more preferably 0.05 to 3% by mass. When the content of the partially neutralized polyacrylic acid is less than 0.05% by mass, the dispersion stability of the water absorbent resin is lowered and the fluidity is deteriorated. On the other hand, even if the content of the partially neutralized polyacrylic acid exceeds 5% by mass, it is difficult to obtain a fluidity improving effect commensurate with the content, which is uneconomical.

  The median particle size of the partially neutralized polyacrylic acid is a value measured by the same method as the median particle size of the water-absorbent resin described above.

(Viscosity, pH of body fluid leakage prevention agent)
The viscosity of the body fluid leakage preventing agent is usually preferably 80,000 to 200,000 mPa · S, more preferably 90,000 to 180,000 mPa · S. When the viscosity of the body fluid leakage preventing agent is less than 80,000 mPa · S, it is easy to enter the body cavity. However, for example, in the case of injection into the throat, it leaks too deep into the throat and causes leakage at the throat. There is a possibility that it cannot be prevented. On the other hand, when the viscosity exceeds 200,000 mPa · S, the fluidity is deteriorated, and it may be difficult to discharge the body fluid leakage preventing agent from the supply pipe.

  The pH of the body fluid leakage preventing agent is usually preferably 6-9. If the pH is lower than 6, the viscosity is insufficient and the viscosity may be outside the effective range. Conversely, when the pH is higher than 9, the viscosity fluctuates and becomes unstable, which may make it difficult to load the body cavity. The pH is used as a barometer to adjust the viscosity of the body fluid leakage preventing agent to an appropriate value.

  Although it does not specifically limit as a neutralizing agent for maintaining the pH of a bodily fluid leakage prevention agent at an appropriate value, For example, a triethanolamine etc. are used. This neutralizing agent only needs to be able to finally adjust the pH of the body fluid leakage preventing agent, and may be added when preparing the mucus base material. The neutralized product may be added after mixing and dispersing to adjust the pH. Alternatively, it may be added both when preparing the mucus substrate and when preparing the body fluid leakage preventing agent.

(Production method of body fluid leakage prevention agent)
As a method for producing a body fluid leakage preventing agent, for example, at least one selected from the group consisting of alcohols, ethers and esters, carboxyvinyl polymer, water absorbent resin and polyacrylic acid partially neutralized product are mixed together A water-absorbing resin is dispersed in a mucus substrate containing at least one selected from the group consisting of alcohols, ethers and esters and a carboxyvinyl polymer, and then a polyacrylic acid partial neutralized product is mixed and dispersed. Disperse the polyacrylic acid partial neutralized product in a mucus substrate containing carboxyvinyl polymer and at least one selected from the group consisting of alcohols, ethers and esters, and then mix and disperse the water-absorbing resin And the like.

  The body fluid leakage preventing agent includes, in addition to the above-mentioned mucosal base material containing at least one selected from the group consisting of alcohols, ethers and esters and a carboxyvinyl polymer, a water absorbent resin and a polyacrylic acid partial neutralized product. , Antibacterial agents, antifungal agents, deodorants, perfumes, antioxidants, pigments and the like may further be included.

  The body fluid leakage preventive agent of the present invention can be applied to the body of humans and animals, and can be loaded into body cavities such as mouth, nose, ear, anus, and woman's vagina to prevent body fluid leakage. Can be prevented.

<Usage example of body fluid leakage prevention agent>
FIG. 4 shows a use state in which a supply pipe is connected to a container loaded with a bodily fluid leakage prevention agent according to an embodiment of the present invention, and the bodily fluid leakage prevention agent in the container is loaded into the body cavity (throat portion) of the corpse through the supply pipe. Indicates.

(Body fluid leakage prevention agent loader)
The loader 1 includes a container 3 for storing the bodily fluid leakage preventing agent 2 and a supply pipe 4 for supplying the bodily fluid leakage preventing agent 2 to the throat B of the corpse. The container 3 includes a syringe 10 and a piston 11. As shown in FIG. 5, the syringe 10 is an integrally molded product made of a resin material, and includes a cylindrical housing portion 12 in which the body fluid leakage preventing agent 2 is filled, and a nozzle portion 13 provided in the housing portion 12. have. An opening 13a through which the bodily fluid leakage preventing agent 2 is discharged is opened at the tip of the nozzle portion 13 of the syringe 10. The nozzle portion 13 has a tapered outer peripheral surface 13b that decreases in diameter toward the tip side. The tapered outer peripheral surface 13b has a shape along the fitting surface 20a of the connecting portion 20 of the supply pipe 4 (details will be described later) shown in FIGS. 6 and 7, and is fitted to the fitting surface 20a. Therefore, when the nozzle portion 13 is inserted into the connection portion 20 of the supply pipe 4, the fitting surface 20a and the tapered outer peripheral surface 13b are in close contact with each other over the entire circumference. Thereby, sufficient liquid-tightness is ensured.

  As shown in FIG. 6, the supply tube 4 includes an insertion tube portion 15 that is inserted from the nostril A toward the throat B. The insertion tube portion 15 has an elongated shape, and is deformable according to the internal shape from the nostril A to the throat B, and the internal passage R of the insertion tube portion 15 is crushed when inserted into the nostril A. Has no firmness. The cross-sectional shape of the insertion tube portion 15 is a circular shape. A first loading hole 16 is opened at the distal end surface (left side in FIG. 6) of the insertion tube portion 15 in the insertion direction. In addition, two second loading holes 17 and two third loading holes 18 are opened 180 degrees apart from each other in the circumferential direction on the peripheral wall portion that is further away from the distal end surface of the insertion tube portion 15. ing. The opening position of the second loading hole 17 and the opening position of the third loading hole 18 are shifted by 90 ° in the circumferential direction of the insertion tube portion 15. The first loading hole 16 has a circular shape, and the second and third loading holes 17 and 18 have a substantially elliptical shape.

  In addition, the 1st-3rd loading holes 16-18 should just be what can load the bodily fluid leakage prevention agent 2 in the insertion pipe part 15 in the throat part B, and are not restricted to said form. That is, the shape, number, and opening position of the first to third loading holes 16 to 18 are the outer diameter and inner diameter of the insertion tube portion 15, the elasticity of the insertion tube portion 15, and the body fluid leakage preventing agent 2 that flows through the internal passage R. It can be arbitrarily set according to conditions such as type and fluidity. For example, the opening areas of the second and third loading holes 17 and 18 may be different from each other. The second and third loading holes 17 and 18 may be circular. Further, any one or two of the first to third loading holes 16 to 18 may be omitted. Although not shown, another loading hole may be opened closer to the base end side than the third loading hole 18 of the insertion tube portion 15.

  A cylindrical intermediate portion 19 is provided at the proximal end portion (right side in FIG. 6) of the insertion tube portion 15. A connecting portion 20 connected to the nozzle portion 13 of the container 3 is provided at the proximal end portion of the intermediate portion 19.

  As shown in FIG. 7, the inner peripheral surface of the intermediate portion 19 and the inner peripheral surface of the insertion tube portion 15 are smoothly connected. Further, the outer diameter of the intermediate portion 19 is set larger than the outer diameter of the insertion tube portion 15 and gradually increases toward the connection portion 20 side. The outer peripheral surface of the intermediate portion 19 is smoothly connected to the outer peripheral surface of the connection portion 20. The thickness of the intermediate portion 19 is thicker than the thickness of the insertion tube portion 15.

  In addition, the inner peripheral surface of the connecting portion 20 on the tip end side (side continuous with the intermediate portion 19) is smoothly connected to the inner peripheral surface of the intermediate portion 19. The inner peripheral surface of the connecting portion 20 has a fitting surface 20a whose diameter increases toward the base end, and the fitting surface 20a is fitted to the tapered outer peripheral surface 13b of the nozzle portion 13. A hole portion 23 (engagement portion) extending in the circumferential direction is provided in an intermediate portion in the axial direction of the connection portion 20. The hole portion 23 is formed at two locations facing each other in the radial direction of the connecting portion 20. The insertion tube portion 15, the intermediate portion 19, and the connection portion 20 are integrally formed using a flexible synthetic resin such as vinyl chloride.

  The insertion tube portion 15 is integrally formed with a stopper 22 that protrudes radially outward from the vicinity of the boundary with the intermediate portion 19 and extends in the circumferential direction. The stopper 22 is positioned so as to hit the nose tip A1 when the first to third loading holes 16 to 18 of the insertion tube portion 15 reach the throat portion B. The stopper 22 may be positioned so as to hit the nose tip A1 when the distal end portion of the insertion tube portion 15 is positioned in the vicinity of the throat portion B. Further, the stopper 22 is not limited to a shape continuously extending in the circumferential direction, and may be a shape intermittent in the circumferential direction of the insertion tube portion 15. Moreover, the protrusion shape which protrudes from the circumferential direction part of the insertion pipe part 15 may be sufficient. Further, the stopper 22 may be formed in another part on the proximal end side of the insertion tube part 15, the intermediate part 19, the connection part 20, or the container 3.

  Further, instead of the stopper 22, a mark (a mark) indicating the amount of insertion of the insertion tube portion 15 into the throat portion B may be provided. The position where the mark is provided may be set similarly to the stopper 22 described above. It is also possible to use the stopper 22 as a mark. A plurality of marks may be provided at intervals in the axial direction of the insertion tube portion 15. The mark may be composed of a protrusion, a recess, or the like, or may be composed of characters, lines, or the like.

  Two projecting portions 14 and 14 (engagement portions) are formed on the outer peripheral surface of the intermediate portion in the axial direction of the nozzle portion 13 so as to be separated in the circumferential direction. As shown in FIG. 7, the protrusions 14 and 14 are disposed so as to be positioned in the hole 23 in a state where the nozzle 13 is completely inserted into the connection part 20 of the supply pipe 4, and the hole 23 It is formed so that it may fit.

  In addition, the number of the protrusion parts 14 and the hole parts 23 is not restricted to two, One, 3 or more may be sufficient. Further, the projecting portion 14 may be formed in an annular shape that is continuous in the circumferential direction of the nozzle portion 13, and may be a recess in which the projecting portion 14 fits in place of the hole portion 23.

  As shown in FIG. 5, a resin cap 25 that closes the opening 13 a is attached to the nozzle portion 13. Thereby, before use, the bodily fluid leakage prevention agent 2 in the accommodating part 12 does not leak from the nozzle part 13.

  The piston 11 is for extruding the bodily fluid leakage preventing agent 2 inside the housing portion 12 from the opening 13 a of the nozzle portion 13. The piston 11 includes an extruding part 11a inserted from the end of the accommodating part 12 opposite to the nozzle part 13, a push bar 11b connected to the extruding part 11a, and an operator operating the push bar 11b via the push bar 11b. And an operation portion 11c for sliding the extrusion portion 11a with the accommodating portion 12. The extrusion part 11a, the push bar 11b, and the operation part 11c are formed of the same resin material as that of the syringe 10. For this reason, after use, the syringe 10 and the piston 11 can be disposed of together.

(Usage example of loader)
The point which connects the container 3 and the supply pipe | tube 4 of the loading device 1 comprised as mentioned above is demonstrated. A cap 25 is attached to the nozzle portion 13 of the syringe 10 filled with the body fluid leakage preventing agent 2. Moreover, the extrusion part 11a of piston 11 is inserted in the inside of syringe 10, and syringe 10 is obstruct | occluded by this.

  First, the cap 25 is removed from the nozzle portion 13. Thereafter, the container 3 and the supply pipe 4 are connected. That is, the nozzle part 13 of the syringe 10 is inserted into the connection part 20 of the supply pipe 4. When the nozzle portion 13 is inserted deeply into the connection portion 20, the tapered surface 13 b of the nozzle portion 13 is pressed against the fitting surface 20 a of the connection portion 20. At this time, since the nozzle portion 13 and the connecting portion 20 are made of a resin material, the tapered surface 13b and the fitting surface 20a are in close contact with each other while being slightly elastically deformed. The protruding portion 14 of the nozzle portion 13 begins to fit into the hole portion 23 of the connecting portion 20 at a timing immediately before the nozzle portion 13 is completely inserted into the connecting portion 20. At this time, since the inclined portion 14 a is formed on the distal end side in the insertion direction of the protruding portion 14, the protruding portion 14 is easily fitted into the hole portion 23. Then, as shown in FIG. 7, the protrusion 14 is engaged with the hole 23 in a state where the protrusion 14 is completely fitted in the hole 23, that is, in a state where the nozzle portion 13 is completely inserted into the connection portion 20. Match. Thereby, the nozzle part 13 is prevented from unexpectedly coming out of the connection part 20. The close contact state between the tapered surface 13b of the nozzle portion 13 and the fitting surface 20a of the connecting portion 20 is maintained, and high liquid tightness can be ensured.

  Since the thickness of the connection portion 20 of the supply pipe 4 is thicker than the thickness of the insertion tube portion 15, the rigidity of the connection portion 20 is higher than that of the insertion tube portion 15. Thereby, even if external force acts on the connection part 20, the contact state of this connection part 20 and the nozzle part 13 can be maintained.

  Next, a procedure for loading the body fluid leakage preventing agent 2 into the throat B will be described. In FIG. 4, C represents the tongue, D represents the trachea, E represents the esophagus, F represents the cervical spine, and G represents the oral cavity.

  First, the insertion tube portion 15 is inserted into the nostril A from the distal end side. At this time, since the insertion tube portion 15 is thinner and more flexible than the intermediate portion 19 and the connection portion 20, it can be easily deformed along the internal shape of the nostril A, and the insertion force can be reduced.

  When the insertion tube portion 15 is inserted deeply into the nostril A and the first to third loading holes 16 to 18 of the insertion tube portion 15 reach the throat B, the stopper 22 hits the nose tip A1. That is, the stopper 22 functions as a mark indicating that the distal end side of the insertion tube portion 15 has reached the throat portion B. When the stopper 22 hits the nose tip A1, the insertion tube portion 15 cannot be inserted any further.

  On the other hand, when the operator stops the insertion of the insertion tube portion 15 with the stopper 22 being far away from the nose tip A1, the distal end side of the insertion tube portion 2 does not reach the throat portion B. If the throat portion B is not reached, the insertion tube portion 15 is further inserted into the nostril A.

  Thereafter, when the push rod 11b of the piston 11 is pushed into the syringe 10, the pushing portion 11a slides on the inner surface of the syringe 10 and proceeds to the nozzle portion 13 side. Thereby, the bodily fluid leakage preventing agent 2 in the syringe 10 passes through the nozzle part 13, passes through the intermediate part 19 of the supply pipe 4 from the opening part 13 a, and is sent into the insertion pipe part 15. The bodily fluid leakage preventing agent 2 fed into the insertion tube portion 15 flows through the internal passage R and is loaded into the throat portion B through the first to third loading holes 16 to 18. When the body fluid leakage preventing agent 2 is loaded, the pressure by the extruding portion 11a acts from the inside of the nozzle portion 13 to the inside of the supply pipe 4, but the tapered surface 13b and the fitting surface 20a are in close contact as described above. When the protrusion 14 is fitted in the hole 23, the nozzle portion 13 is prevented from unexpectedly coming out of the connection portion 20. Further, the body fluid leakage preventing agent 2 is prevented from leaking from between the nozzle portion 13 and the connecting portion 20.

  Further, when loading the body fluid leakage preventing agent 2 into the throat B, for example, part or all of the second loading hole 17 of the insertion tube portion 15 is blocked from the inner wall of the nostril A or the inner wall of the throat B. It is possible that In this case, the bodily fluid leakage preventing agent 2 is discharged from the third loading hole 18, passes between the outer peripheral surface of the insertion tube portion 15 and the inner wall of the nostril A, is guided to the throat portion B, and is first loaded. The throat B is loaded from the hole 16.

  Further, as a procedure for loading the bodily fluid leakage preventing agent 2 into the throat part B, as described above, after connecting the container 3 and the supply pipe 4, the insertion pipe part 15 of the supply pipe 4 is inserted into the nostril A. In addition, there is a method in which the container 3 and the supply pipe 4 are connected after the insertion pipe portion 15 of the supply pipe 4 is inserted into the nostril A.

  In the latter method, first, the insertion tube portion 15 is inserted from the nostril A toward the throat B. And the nozzle part 13 of the syringe 10 is inserted in the connection part 20 of the supply pipe 4, and the protrusion part 14 is engaged with the hole part 23. FIG. Thereby, the container 3 and the supply pipe 4 are connected. Then, by operating the piston 11, the bodily fluid leakage preventing agent 2 is loaded into the throat B through the supply pipe 4.

  Therefore, according to the connection structure between the container 3 and the supply pipe 4 according to this embodiment, the protrusion 14 is formed on the outer peripheral surface of the nozzle part 13 of the container 3 and the inner peripheral surface of the connection part 20 of the supply pipe 4. A hole 23 is formed in the substrate. And since the protrusion part 14 was fitted in the hole 23 in the state which inserted the nozzle part 13 in the connection part 20, the connection of the container 3 and the supply pipe | tube 4 can be ensured. Thereby, it can prevent that the bodily fluid leakage prevention agent 2 leaks from a connection part during the loading operation | work to the dead body of the bodily fluid leakage prevention agent 2. FIG. Further, it is possible to prevent the supply pipe 4 from being detached from the container 3.

  Moreover, since the bodily fluid leakage preventing agent 2 is pushed out from the syringe 10 by the piston 11 sliding in the syringe 10, the bodily fluid leakage preventing agent 2 can be reliably held in the syringe 11 before use. On the other hand, during the loading operation, the bodily fluid leakage preventing agent 2 can be loaded into the throat B by a simple operation of pushing the piston 11 into the syringe 10. In particular, since the bodily fluid leakage preventing agent 2 in the syringe 10 can be pushed out with a light force to the end, the workability is excellent.

  In addition, after loading the bodily fluid leakage preventing agent 2 into the throat B, when the loader 1 is discarded, the container 3 and the supply pipe 4 may be connected or separated. . When the container 3 and the supply pipe 4 are separated from each other, the nozzle part 13 of the syringe 10 may be strongly pulled out from the connection part 20 of the supply pipe 4.

<Examples about body fluid leakage preventing agent>
Next, the bodily fluid leakage preventing agent of the present invention will be described based on examples. EXAMPLES The present invention will be specifically described below with reference to examples and comparative examples, but the present invention is not limited to these examples.

(Examples 1-7 and Comparative Example 1)
[Preparation of body fluid leakage prevention agent]
Preparation of the bodily fluid leakage preventive agent which concerns on Examples 1-7 and Comparative Example 1 is demonstrated. Ethylene glycol and polyethylene glycol as a solvent were put in a container equipped with a stirrer, carboxyvinyl polymer was added little by little while stirring, and the mixture was stirred for 2 to 8 hours. A water-absorbent resin was added to the obtained mucus base material and sufficiently stirred. About the Example, the polyacrylic acid partial neutralized material was further added, and it fully stirred. Thereafter, triethanolamine was added dropwise little by little while stirring the mucus base material in which the water-absorbent resin was dispersed, thereby preparing a body fluid leakage preventing agent having a pH of 7.0. The blending ratios and viscosities of the components of the examples and comparative examples are as shown in Table 1.

  The following were used as each component.

Ethylene glycol: (Nippon Alcohol Sales Co., Ltd.)
PEG200: Polyethylene glycol having a number average molecular weight of 200 (manufactured by NOF Corporation)
Carboxyvinyl polymer: Trade name “Hibiswako” manufactured by Wako Pure Chemical Industries, Ltd. Water-absorbent resin TYPEI: Trade name “Aquakeep 10SH-PF”, manufactured by Sumitomo Seika Co., Ltd. Polyacrylic acid partially neutralized product: Trade name “ ACCANA AP-70 ”manufactured by Sumitomo Seika Co., Ltd. Triethanolamine: (Mitsui Chemicals, Inc.)
“Aquakeep 10SH-PF” is a granular water-absorbing resin having a median particle diameter of 160 μm, and the water absorption speed of physiological saline is 2 seconds. “Acpana AP-70” is a partially neutralized polyacrylic acid having a median particle diameter of 70 μm and a neutralization degree of 70%.

[Characteristic evaluation test device for body fluid leakage prevention agent]
Extrusion characteristics of each of the body fluid leakage preventing agents of Examples 1 to 7 and Comparative Example 1 using a syringe were evaluated by a test apparatus shown in FIG.

  The test apparatus was configured using a syringe pump “MCIP-VII” of the “Minato Concept” limited company and “DPCO-II” of the “MCIP / DPCO series”. The control device 50 includes a control unit 51, a display unit 52, a setting unit 53, a pressure detection unit 54, and a discharge pressure detection unit 55. The syringe 10 is set on the measurement table 60. The measurement table 60 includes a placement portion 61 for fixing the syringe 10 and an attachment portion 62 for attaching the operation portion 11 c of the piston 11. A lower portion 62a of the attachment portion 62 is provided on the measurement table 60 so as to be slidable in the syringe longitudinal direction. The drive unit 70 slides the attachment unit 62 based on a signal from the control unit 51.

  The setting unit 53 performs initial settings such as a feed speed (or feed amount) in the drive unit 70, a drive start of the drive unit, and a drive end setting. The pressure detector 54 detects the pressure received by the mounting portion 62 when the mounting portion 62 is pushed in at a constant speed. The discharge amount detection unit 55 discharges the body fluid leakage prevention agent discharged from the first, second and third loading holes 16, 17, 18 of the supply pipe 4 when the attachment unit 62 is pushed in at a constant speed. The amount (or the advance amount of the pushing portion 11a of the piston 11) is detected.

[Evaluation method]
Next, the evaluation method will be described. The container 2 filled with the bodily fluid leakage preventing agent of Examples 1 to 6 and Comparative Example 1 is connected to the supply pipe 4, and the syringe 10 is set on the mounting portion 61 of the measurement table 60. Then, the operation portion 11 c of the piston 11 is attached to the attachment portion 62. In this state, the control device 50 is operated. Specifically, the drive unit 70 is operated based on a signal from the control unit 51. By the operation of the drive unit 70, the mounting unit 62 (the operation unit 11c of the piston 11) moves forward at a constant speed, and the body fluid leakage preventing agent in the container 10 is supplied to the first, second, and third loading holes 16, 17 and 18 are discharged by a fixed amount. The pressure received by the operating unit 11c during discharge is detected by the pressure detection unit 54, and the amount discharged from the syringe is detected by the discharge amount detection unit 55. FIG. 9 is a graph with the discharge pressure on the vertical axis and the discharge amount on the horizontal axis. The temperature of the measurement chamber was set to room temperature (25 ° C.).

  As shown in FIG. 9, in all of Examples 1 to 6, the discharge pressure rises from slightly less than 300 KPa to nearly 400 KPa immediately after the start of discharge. Thereafter, the body fluid leakage preventing agent is discharged at a substantially constant discharge pressure, or the body fluid leakage preventing agent is discharged while the discharge pressure is gradually increased. And the discharge pressure has fallen sharply just before the end of discharge. On the other hand, in Comparative Example 1, the discharge pressure initially rises in the same manner as in the example, but the rise is slightly gentle on the way. Thereafter, the discharge pressure fluctuates greatly. In particular, in Comparative Example 1, the discharge pressure is rapidly increased near the end of the discharge of the body fluid leakage preventing agent.

  From this, in Comparative Example 1, when the bodily fluid leakage preventing agent is pushed out from the syringe 10, the extrusion resistance increases intermittently from the middle, and a large force is exerted when the bodily fluid leakage preventing agent is pulled out from the syringe 10. I understand that it is necessary. On the other hand, in Examples 1-6, after discharge pressure rises, there is no big fluctuation | variation of discharge pressure until a bodily fluid leakage prevention agent is extruded from the syringe 10. FIG. Therefore, the bodily fluid leakage preventing agent can be smoothly pushed out with a relatively light force.

  According to Examples 1-6, the discharge pressure at the time of loading the bodily fluid leakage preventing agent into the body cavity decreases as the blending ratio of the partially neutralized polyacrylic acid increases (FIG. 9). Moreover, the viscosity of the bodily fluid leakage preventing agent is also low (Table 1). This is because the partially neutralized polyacrylic acid enhances the dispersion stability of the water-absorbent resin in the mucus substrate and suppresses phase separation of the body fluid leakage preventing agent when extruded by the piston. Moreover, it turns out that the high phase-separation inhibitory effect is acquired even if polyacrylic acid partial neutralized material is a trace amount of 0.05 mass% from the comparison with Example 1 and the comparative example 1. FIG.

  When the polyacrylic acid partial neutralized product was increased stepwise from 0.05 to 0.5% by mass, the viscosity of the body fluid leakage preventing agent decreased (Table 1). Moreover, since the discharge pressure also decreased, the evaluation test was omitted for Example 7. Moreover, what made the polyacrylic acid partial neutralized material 5 mass% thought that it was not necessary to make and confirm as an Example, and was abbreviate | omitted. This 5% by mass is a practically preferable upper limit value in order to avoid an increase in cost.

  Using this result as a reference, we tested how the operator felt when actually working. Five workers actually pushed the piston to push out the bodily fluid leakage preventing agent 2 in the syringe 10 from the supply pipe 4. About the said Examples 1-7, evaluation that it can extrude smoothly was obtained. In Examples 1 to 7, when the polyacrylic acid partial neutralized product increases, the viscosity decreases slightly and the discharge pressure tends to decrease slightly. However, when the bodily fluid leakage prevention agent can be pushed out at a substantially constant pressure, or when the fluctuation of the discharge pressure is small, the operator should not feel the magnitude of the discharge pressure even if the discharge pressure is somewhat large or small. I understood.

  On the other hand, in Comparative Example 1, since the discharge pressure suddenly rose in the latter half of the extrusion of the body fluid leakage preventing agent, it was necessary to apply a strong force in the second half, and the result was that all five workers felt a burden. In addition, there were two workers who felt uncomfortable in the extrusion operation due to fluctuations in the discharge pressure during the extrusion of the body fluid leakage preventing agent.

(Examples 8 to 15)
The body fluid leakage preventing agents according to Examples 8 to 15 shown in Table 2 were prepared according to the method for preparing the body fluid leakage preventing agent described above. Examples 8-15 employ | adopted ethylene glycol, polyethyleneglycol, and glycerin as a solvent, all are 3 g of polyacrylic acid partial neutralization products, and in Examples 9-15, TYPEI and TYPEII were used as a water absorbing resin. . “Water-absorbing resin TYPEII” is a trade name “Aquakeep SA60N TYPEII” manufactured by Sumitomo Seika Co., Ltd., and is a spherical aggregated water-absorbing resin with a median particle diameter of 310 μm. 30 seconds. Table 2 lists the component blending amounts and viscosities of each body fluid leakage preventing agent.

  Extrusion characteristics of the body fluid leakage preventing agents of Examples 8 to 15 using a syringe were evaluated by the test apparatus shown in FIG. The results are shown in FIG.

  According to FIG. 10, in Examples 8 to 15, the discharge pressure rose from a little less than 300 KPa to nearly 400 KPa immediately after the start of discharge, and thereafter the body fluid leakage preventing agent was discharged without any significant change in the discharge pressure. Then, the discharge pressure suddenly decreased just before the end of the discharge. From this, it can be seen that, according to Examples 8 to 15, the operator can smoothly extrude the body fluid leakage preventing agent from the syringe with a relatively light force. In Examples 8 to 15, the blending amount of the water-absorbing resin TYPEII increases in order, but the discharge pressure is not necessarily proportional to the increase in the blending amount of the water-absorbing resin TYPEII. As can be seen from Table 2, this is considered to be due to the influence of the viscosity of the body fluid leakage preventing agent.

  That is, according to Table 2, Examples 9-15 which used together TYPEI and TYPEII as a water absorbing resin have a viscosity larger than Example 8 which contains only TYPEI as a water absorbing resin. However, in the case where the blending amount of the water absorbent resin TYPEII is not large as in Examples 9 to 13, the increase in the blending amount does not necessarily lead to the increase in the viscosity.

  Therefore, it can be seen that when the polyacrylic acid partial neutralized product is blended with the body fluid leakage preventing agent, the increase in viscosity can be suppressed to a certain extent even if the blending amount of the water-absorbing resin TYPE II is increased. It can also be seen that when TYPEI and TYPEII are used in combination as the water-absorbing resin, the amount of the water-absorbing resin blended in the body fluid leakage preventing agent can be increased, which is advantageous in preventing body fluid leakage in cases where the body fluid leakage amount is large.

  In Example 15, the blending ratio of the water-absorbent resin TYPEI and the water-absorbent resin TYPEII is about 36% by mass. The ratio of the water absorbent resin TYPEII to the total amount of the water absorbent resin TYPEI and the water absorbent resin TYPEII is about 40%. In the combined use of the water-absorbent resin TYPEI and the water-absorbent resin TYPEII, when the mixing ratio of the water-absorbent resin in the body fluid leakage preventing agent is 36% by mass or less, if the ratio of the water-absorbent resin TYPEII is 40% or less, the body fluid It can be said that there is no hindrance to the extrusion of the leakage preventing agent.

(Examples 16 to 21 and Comparative Example 2)
The body fluid leakage preventing agents according to Examples 16 to 21 and Comparative Example 2 shown in Table 3 were prepared according to the method for preparing the body fluid leakage preventing agent described above. Examples 16 to 21 and Comparative Example 2 are cases where TYPEI and TYPEII are used in combination as the water-absorbing resin, and the blending amount of the partially neutralized polyacrylic acid is changed. Table 3 lists the component blend amounts and viscosities of each body fluid leakage preventing agent.

  Extrusion characteristics of the body fluid leakage preventing agents of Examples 16 to 21 and Comparative Example 2 with a syringe were evaluated by a test apparatus shown in FIG. The results are shown in FIG.

  According to FIG. 11, in Examples 16 to 21, the discharge pressure rose to around 300 KPa immediately after the start of discharge, and thereafter the body fluid leakage preventing agent was discharged without any significant change in the discharge pressure. Then, the discharge pressure suddenly decreased just before the end of the discharge. From this, according to Examples 16-21, it turns out that an operator can extrude a bodily fluid leakage prevention agent smoothly with a comparatively light force from a syringe. On the other hand, in Comparative Example 2, the discharge pressure fluctuates greatly such that the discharge pressure rises to about 400 KPa, drops to about 360 KPa, and finally rises to about 400 KPa again.

  From a comparison between Example 16 and Comparative Example 2, it can be seen that a high effect of suppressing phase separation can be obtained even when a small amount of polyacrylic acid partial neutralized product is added (0.5 g; approximately 0.43 mass%). Moreover, although the compounding quantity of the polyacrylic acid partial neutralized material has increased in steps in Examples 16-21, according to FIG. 11, there is no big difference in those body fluid leakage prevention agent extrusion characteristics. Therefore, it can be seen that even if the blending amount of the partially neutralized polyacrylic acid exceeds 5 g (about 4% by mass), it is merely uneconomical and an effect commensurate with the increase cannot be obtained.

  In addition, although Example 14 of Table 2 and Example 19 of Table 3 have the same composition of a bodily fluid leakage prevention agent, both differ in a viscosity and accompanying it, the extrusion characteristic of a bodily fluid leakage prevention agent (FIG. 10). 11) is also slightly different. This difference in viscosity is based on the difference in stirring time when preparing the mucus base material of the body fluid leakage preventing agent. That is, in Examples 1 to 15 and Comparative Example 1, the stirring time was 7 hours, and in Examples 16 to 21, Comparative Example 2, and Examples 22 to 25 described later, the stirring time was 8 hours.

(Examples 22 to 25)
The bodily fluid leakage preventing agents according to Examples 22 to 25 shown in Table 4 were prepared according to the method for preparing the bodily fluid leakage preventing agent described above. Examples 22 to 25 are cases in which only TYPE II is adopted as the water-absorbing resin, and the blending amount thereof is changed. Table 4 lists the component blending amounts and viscosities of each body fluid leakage preventing agent.

  Extrusion characteristics of the bodily fluid leakage preventing agents of Examples 22 to 25 using a syringe were evaluated by the test apparatus shown in FIG. The results are shown in FIG.

  According to FIG. 12, in Examples 22 to 24, after the discharge pressure rises to about 300 to 350 KPa, the body fluid leakage preventing agent is discharged without the discharge pressure changing greatly. Even in Example 25 in which the blending amount of the water-absorbing resin TYPE II was 117 g (about 60% by mass), the discharge pressure initially exceeded 400 KPa, but thereafter the body fluid leakage preventive agent did not change greatly. Is discharging. From this, even when using TYPEII alone as a water-absorbing resin, by blending a partially neutralized polyacrylic acid, the operator can smoothly extrude the body fluid leakage prevention agent from the syringe with a relatively light force I understand. Moreover, even if it raises the compounding quantity of a water absorbing resin to about 60 mass%, it turns out that there is no trouble in discharge of a bodily fluid leakage prevention agent.

  From the results of Examples 1 to 25 described above, when extruding the bodily fluid leakage preventing agent, it is possible to extrude at a stable pressure value from the initial stage of pushing in the piston until all the bodily fluid leakage preventing agent in the syringe is completely dispensed. In particular, it was found that even when the discharge of the bodily fluid leakage preventive agent is about to end, the pressure does not increase rapidly and can be pushed out smoothly. Since the polyacrylic acid partially neutralized product improves the dispersion stability of the water-absorbent resin, only the mucus substrate comes out first from the start to the end of the discharge of the body fluid leakage preventing agent, and the water-absorbent resin is relatively It is prevented that a large amount remains. Even if the remaining amount of the solvent decreases in the second half of the discharge, not only the water-absorbent resin but also the polyacrylic acid partially neutralized product with good fluidity remains in the container, so the pressure does not rise suddenly, It can be extruded smoothly.

  In the said embodiment, although the accommodating part 12 of the container 3 was comprised with the syringe 10, you may comprise using members, such as not only this but a softness | flexibility. In this case, what is necessary is just to squeeze the bodily fluid leakage prevention agent 2 from a accommodating part.

  Moreover, you may make it insert the supply pipe | tube 4 of embodiment toward the throat part B from the oral cavity G (shown in FIG. 4). Alternatively, when inserting into the throat from the oral cavity, another supply tube set to a length, a bend, and an inner diameter (outer diameter) suitable for the same may be used.

  Further, when the supply pipe 4 is used for an infant, it is preferable to provide a mark or a stopper at a site about 5 cm from the tip of the supply pipe 4. Furthermore, for children, it is preferable to provide a mark or a stopper at a site about 8 cm from the distal end of the insertion tube portion 15. In addition, when the supply tube 4 is used for both insertion from the nostril A to the throat B and insertion from the oral cavity G to the throat B, the above-described two marks and stoppers are provided. You may do it. In addition, a mark for children is formed widely in the axial direction of the supply pipe 4 and used as a mark when the front end side of the mark (the front end side of the supply pipe 4) is inserted from the oral cavity G, and the rear end side (supply pipe) 4 may be used as a mark when inserting through the nostril A. A supply pipe for infants, a supply pipe for children, and a supply pipe for adults may be set as a set, and may be selected and used as necessary. The supply pipe for infants, the supply pipe for children, and the supply pipe for adults may be provided with identification marks, or the colors of these supply pipes may be different from each other. Further, the size of the container 3 may be changed for infants, children, and adults. Moreover, you may change the component and loading amount of the bodily fluid leakage prevention agent 2 for infants, children, and adults.

  Note that the loader is not limited to the above-described embodiment, and may be another loader, or may be other loading means instead of the loader.

  INDUSTRIAL APPLICABILITY The present invention can be used as a body fluid leakage preventing agent loaded in body cavities such as the mouth, nose, ear, anus, and cavity of human and animal bodies.

DESCRIPTION OF SYMBOLS 1 Loading device 2 Body fluid leakage prevention agent 3 Container 4 Supply pipe 10 Syringe 11 Piston 12 Housing | casing part 13 Nozzle part 14 Protrusion part (engagement part)
15 Insertion tube parts 16-18 First to third loading holes 22 Stopper (mark)
23 Hole (engagement part)

Claims (10)

A bodily fluid leakage preventive agent loaded into the body cavity of a corpse,
Crosslinking in a mucus substrate containing at least one selected from the group consisting of alcohols, ethers and esters, wherein the saline water absorption rate is 80 seconds or less and the median particle size is 20 μm or more and 400 μm or less A body fluid leakage preventing agent comprising a non-crosslinked polyacrylic acid partial neutralized product in which a water-absorbing resin of a type is dispersed and a median particle diameter is 10 to 100 μm as a dispersion stabilizer. As the water absorbent resin, according to claim water absorption rate of saline water absorbent resin is not more than 10 seconds, the water absorption rate of saline containing at least one of the water-absorbent resin is 80 seconds or less 15 seconds or more 1. The bodily fluid leakage preventive agent according to 1. As the water absorbent resin, according to claim 1, the water absorption rate of saline containing a water-absorbent resin is not more than 10 seconds, the water-absorbent resin is water-absorption rate of saline to 80 seconds 15 seconds Body fluid leakage prevention agent. Among the water-absorbing resins having a median particle diameter of 20 μm or more and 300 μm or less and a water absorption rate of 15 to 80 seconds for the physiological saline, The body fluid leakage preventing agent according to claim 2 or 3 , wherein the unit particle diameter is 180 µm or more and 400 µm or less. The body fluid leakage preventing agent according to any one of claims 1 to 4 , wherein the neutralization degree of the partially neutralized polyacrylic acid is 40% or more and 80% or less. The body fluid leakage preventing agent according to any one of claims 1 to 5 , wherein the content of the water absorbent resin is 10% by mass or more and 60% by mass or less. The body fluid leakage preventing agent according to any one of claims 1 to 6 , wherein the content of the partially neutralized polyacrylic acid is 0.05% by mass or more and 5% by mass or less. The bodily fluid leakage preventing agent according to any one of claims 1 to 7 , wherein the bodily fluid leakage preventing agent has a viscosity of 80,000 mPa · S or more and 200,000 mPa · S or less. The bodily fluid leakage preventing agent according to any one of claims 1 to 8 , wherein the bodily fluid leakage preventing agent has a pH of 6 or more and 9 or less. The body fluid leakage preventing agent according to any one of claims 1 to 9 , wherein the alcohol is at least one of ethylene glycol, propylene glycol, diethylene glycol, polyethylene glycol, and glycerin.